GEN - Genetic Engineering and Biotechnology News

ESGCT 2025: Altos Labs’ Scientific Founder Targets ‘Mesenchymal Drift’ in Efforts to Combat Diseases of Aging

Izpisua Belmonte, PhD, Altos Labs, advocates a disease-agnostic approach, but first, he said, “we must understand the mechanism, something that is core to the cell.” ...
PharmiWeb

Mesenchymal Stem Cells Market Growth Strategies and Competitive Landscape

System MarketThe global Mesenchymal Stem Cells Market is valued at USD 3.82 Billion in 2024 and is projected to reach a value of USD 9.08 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...
TipRanks on MSN

Mesoblast reports Q2 Ryoncil revenue up 66% y/y

Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This ...

RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company ...

Global Mesenchymal Stem Cells/Medicinal Signaling Cells Landscape 2025: Approvals by Region, Bioengineering Trends, and Supply Chain Industrialization

The MSC market offers significant opportunities in regenerative medicine, cosmeceuticals, and cultured meat production. Leveraging their regenerative and immuno-evasive properties, MSCs are key in ...

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

The new permanent J-Code, J3402, provides a standardized, clear, permanent, and specific billing pathway for Ryoncil ® by Medicaid, facilitating reimbursement and broader patient access for this ...

Stem Cell Manufacturing Market to Hit Valuation of US$ 65.49 Billion by 2033 | Astute Analytica

Stem cell manufacturing landscape is rapidly advancing, driven by major clinical trial successes and new therapy approvals. A ...
TipRanks on MSN

Mesoblast’s U.S. Origin Cell Therapies Exempt from Tariffs

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its allogeneic cell therapy products, manufactured ...
manilatimes

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

Ryoncil® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic License ...
Medindia

Gallant Achieves FDA "Technical Section Complete" for Reasonable Expectation of Effectiveness, Advancing First Ready-to-Use Stem Cell Therapy

The product is sonruvetcel suspension for injection – a potential first-in-class, uterine-derived allogeneic mesenchymal stromal cell therapy for cats with refractory feline ...
Frontiers

Advances in human amniotic placenta membrane-derived mesenchymal stromal cells (hAMSCs) for regenerative medicine: enhancing therapeutic potential with biomaterials and scaffolds

Mesenchymal stromal cells (MSCs) derived from the human placenta amniotic membrane (hAMSCs) have emerged as a promising option in regenerative therapies due to their multipotent differentiation and ...